🇺🇸

Distress Insolvency

· daily

US Corporate Distress Financial Stress SEC Filings — September 14, 2026

This USA Corporate Distress & Bankruptcy digest for September 14, 2026, reveals a stark dispersion in corporate health. The critical event is Cambium Networks Corp's UK subsidiary filing for administration, a de facto bankruptcy proceeding, accompanied by an aggressive 53.6% workforce cut with zero severance, signaling severe financial distress. In stark contrast, SmartKem, Inc. successfully resolved its Nasdaq delisting risk by regaining bid price compliance, a positive turnaround signal. Texas Capital Bancshares' voluntary delisting from Nasdaq is a low-materiality, strategic listing move, not distress-driven, but adds a technical delisting data point. The period-over-period data (e.g., YoY revenue declines, margin compression) was not disclosed in these filings, but the operational metrics (53.6% workforce cut) and forward-looking implications (asset sales, entity wind-down) provide actionable insights. Insider activity and capital allocation data were absent, but the magnitude of the workforce reduction and administration filing creates a high-risk signal. The core theme is binary: one company entering deep distress with an uncertain asset recovery, versus another emerging from compliance trouble.

3 high priority 3 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 14, 2026

The sole filing in this stream, Cambium Networks Corp's 8-K, reveals a severe distress event: its UK subsidiary CNL entered administration on September 14, 2026, under the Insolvency Act 1986, with administrators appointed to sell assets. Concurrently, the company terminated 260 employees (53.6% of its workforce) without severance, including a senior executive, signaling acute liquidity constraints and a strategic retreat. The absence of forward-looking guidance, insider activity, or capital allocation data in the enriched filing underscores the sudden and reactive nature of the insolvency. This event highlights a broader pattern of cross-border insolvency risk for US-listed companies with UK operations, and the potential for cascading effects on the parent company's balance sheet and operations. The 10/10 materiality rating and negative sentiment demand immediate investor attention to Cambium's remaining entities and the potential for further restructuring or going-concern disclosures.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 11, 2026

On September 11, 2026, three US micro-cap companies received Nasdaq deficiency notices for failing to maintain the $1.00 minimum bid price, creating a concentrated distress event in the small-cap equity space. Fractyl Health (GUTS) faces immediate delisting after exhausting its 180-day grace period and is pursuing a reverse stock split (1-for-5 to 1-for-15) to regain compliance. Greenland Technologies (GTEC) secured a second 180-day extension until March 8, 2027, providing temporary relief but highlighting persistent structural weakness. Glimpse Group (BTLN) received a final delisting determination and has only until September 18 to appeal, creating the most time-sensitive risk. All three companies share a common distress pattern: prolonged sub-$1 trading, reliance on reverse stock splits as a remedy, and uncertain outcomes pending Nasdaq hearings. The cluster of filings on a single day suggests a broader market rotation away from micro-cap names with weak fundamentals, as no company reported positive period-over-period revenue growth or insider buying in the enriched data. The absence of any capital allocation actions (dividends, buybacks) across all three filings confirms severe financial constraints, with management teams focused entirely on survival rather than shareholder returns.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 10, 2026

The 8 filings in this stream reveal a bifurcated landscape: a wave of voluntary, non-distressed listing transfers from NYSE to the Texas Stock Exchange (TXSE) by three energy MLPs (Sunoco LP, Energy Transfer LP, USA Compression Partners, LP) contrasts sharply with acute, fundamental distress signals from two micro-cap biotechs (20/20 Biolabs, iSpecimen) facing Nasdaq delisting for equity deficiencies. A third entity, the Bitwise Dogecoin ETF, is undergoing a complete liquidation and shutdown, representing a total capital loss for remaining holders. The TXSE transfers, while not distress events, create a temporary dislocation and signal a strategic shift in listing venue preferences. The core distress signals are concentrated in the healthcare/life sciences sector, where both 20/20 Biolabs and iSpecimen are critically undercapitalized, with negative equity positions and imminent compliance deadlines. A positive outlier is Global Interactive Technologies, which swiftly resolved a delinquency notice, demonstrating strong financial controls. The overarching theme is a 'hollowing out' of marginal, speculative assets (crypto ETF, cash-poor biotechs) while stable, cash-flowing energy partnerships execute a strategic realignment.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 09, 2026

The sole filing in today's distress digest—Iveda Solutions' 8-K regarding a second 180-day Nasdaq grace period—underscores a persistent micro-cap distress theme: companies repeatedly kicking the can on minimum bid price compliance without a clear turnaround catalyst. While the extension to March 1, 2027, provides temporary relief, the absence of any period-over-period financial improvement data, insider buying, or capital allocation actions (no buybacks, no debt restructuring) in the enriched analysis signals a high risk of eventual delisting. The company's reliance on a potential reverse stock split as a primary cure is a classic distress signal, often leading to further price erosion post-split. For the broader portfolio, this filing reinforces that passive compliance extensions, without operational or financial fixes, are a bearish indicator for equity holders.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 08, 2026

This digest captures severe corporate distress signals across four US-listed companies, with two filing for Chapter 11 bankruptcy (Synergy CHC Corp. and Sangamo Therapeutics) and two receiving Nasdaq delisting warnings (Aterian, Inc. and Estrella Immunopharma). The filings reveal a common theme of liquidity crises and market value deterioration, with Synergy CHC entering bankruptcy with a complete board resignation and Sangamo posting a monthly loss of $11.2M despite $16.9M cash on hand. Both Aterian and Estrella face 180-day compliance windows to regain Nasdaq listing standards, but Estrella's failure to meet alternative equity or income thresholds makes its path particularly precarious. From a period-over-period perspective, Sangamo's cash burn of $11.2M in a single month (including $4.2M in reorganization costs) against $16.9M total cash implies a runway of less than 2 months, while Synergy's board exodus signals zero confidence in a going-concern turnaround. The aggregate market implication is a heightened risk of equity value destruction, with potential for distressed asset plays in the biotech and consumer health sectors.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 08, 2026

The two filings in this stream highlight a deeply distressed corporate landscape in the US, with both companies undergoing Chapter 11 bankruptcy proceedings. Synergy CHC Corp. filed for Chapter 11 on September 4, 2026, triggering a complete board overhaul and appointment of a Chief Restructuring Officer, signaling a likely liquidation or major reorganization. Sangamo Therapeutics, in its first monthly operating report post-petition, reveals a cash burn of $11.2 million in July 2026, with total liabilities of $97.1 million against $16.9 million cash, indicating a precarious liquidity position. Both companies exhibit negative sentiment and high materiality, with no positive forward-looking indicators. The lack of any period-over-period revenue or margin data in these filings suggests a focus on survival rather than operational performance. The sector theme is one of acute financial distress, with governance instability and rapid cash depletion as key risk factors.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 04, 2026

The September 4, 2026, corporate distress landscape is dominated by a cluster of Nasdaq and NYSE American noncompliance events, with 5 of 7 filings involving delisting risks from equity, bid price, or public float deficiencies. A notable trend is the severe equity erosion across micro-cap biotech and tech firms: Arcadia Biosciences reported just $633K in equity (vs. $2.5M minimum), Quince Therapeutics posted negative equity of -$35.3M (vs. $10M minimum), and Matinas BioPharma fell to $1.8M (vs. $2.0M minimum). The only positive signal is RE/MAX Holdings' going-private merger completion, which removed a distressed public company from the market. Insider activity is absent across all filings, suggesting management teams are either unable or unwilling to signal confidence through purchases. The aggregate forward-looking data reveals a critical catalyst calendar: 4 companies face compliance plan submission deadlines by October 15, 2026, creating a compressed window for restructuring or capital raises.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 03, 2026

The September 3, 2026, corporate distress landscape is dominated by Nasdaq listing compliance issues, with three of four filings directly involving deficiency notices. A clear pattern emerges: two companies (Gulf Resources, Fly-E Group) face late filing violations under Rule 5250(c)(1), while N2OFF struggles with a minimum stockholders' equity deficiency under Rule 5550(b)(1). The most critical development is the high materiality (9/10) of Gulf Resources' ongoing delinquency, which poses a real delisting threat. In contrast, Fly-E Group resolved its issue within hours, and CXApp successfully cured a year-long bid price deficiency via a reverse stock split, providing a positive counterpoint. The period-over-period data reveals a stark divergence in financial health: N2OFF's equity of $1.78M is 29% below the $2.5M threshold, while CXApp's proactive capital action (reverse split) restored compliance. No insider trading activity was reported in any filing, limiting conviction signals. The forward-looking data is critical, with N2OFF's October 15, 2026, compliance plan deadline and Gulf Resources' unspecified extended filing deadline serving as key catalyst dates. The overarching theme is that while Nasdaq provides cure periods, the underlying financial distress at N2OFF and Gulf Resources remains unresolved, creating binary risk/reward scenarios for investors.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 02, 2026

The six filings paint a stark picture of corporate distress concentrated in the small-cap and micro-cap space, with three companies facing imminent Nasdaq delisting (Triller, IRIDEX, Reborn Coffee) and one (TScan Therapeutics) executing a drastic restructuring to avoid a cash crunch. A common theme is severe capital constraints forcing strategic pivots or asset sales, as seen in TScan's 75% workforce reduction and Twinlab's assignment for the benefit of creditors. Period-over-period data is limited in these event-driven filings, but the aggregate signals point to a sector-wide liquidity crisis among undercapitalized life sciences and consumer companies. The most actionable intelligence lies in the divergence between companies with viable turnaround plans (TScan, cbdMD/Twinlab) and those with unresolved compliance issues (Triller, Reborn Coffee). Insider activity is notably absent across all filings, suggesting management teams are either constrained or lacking conviction. The forward-looking catalyst calendar is dominated by Nasdaq compliance deadlines and IND filings, creating a binary event-driven trading environment.

6 high priority 6 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 02, 2026

The sole filing in this session involves Twinlab Consolidated Holdings, Inc., which is undergoing an Assignment for the Benefit of Creditors (ABC) proceeding—a common alternative to Chapter 11 bankruptcy. cbdMD, Inc. has entered a definitive asset purchase agreement to acquire Twinlab's operating assets and brands, including Twinlab, Reserveage, Metabolife, and Alvita Tea. The transaction is expected to boost cbdMD's trailing twelve-month revenue to approximately $30 million, a 40% increase over its standalone revenue, though this figure is illustrative and not guaranteed. The deal is subject to court approval, reflecting the insolvency-driven nature of the sale. No period-over-period comparisons, insider activity, or forward-looking guidance were provided in the filing, limiting trend analysis. The mixed sentiment stems from the strategic opportunity for cbdMD versus the underlying distress of Twinlab. This is a quiet session with no other bankruptcy or insolvency filings, making this the sole actionable event.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 01, 2026

The digest reveals a sharp and concentrated wave of distress across eight US-listed companies, centred overwhelmingly on Nasdaq listing deficiencies and acute solvency risks. The dominant theme is a cascade of late-filing violations, with four separate companies (XTI Aerospace, Borealis Foods, CID Holdco, Heritage Distilling) receiving delinquency notices for missing their Q2 2026 10-Q deadlines, pointing to systemic accounting or disclosure issues. The most severe event is BioXcel Therapeutics entering Chapter 11 bankruptcy, a binary outcome that underscores the ultimate crystallization of distress. Insider activity is notably absent across all filings, weakening management's credibility as a signalling tool. Period-over-period comparisons were sparse in these event-driven disclosures, but the sheer density of going-concern warnings (XTI Aerospace) and compound listing failures (authID, CID Holdco) signals that a subset of micro-cap names is facing a liquidity and governance crunch. The critical market implication is that the delisting risk is not isolated; each new deficiency creates a compounding risk that can accelerate the timeline to bankruptcy or forced M&A, as seen in BioXcel's case.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 31, 2026

This digest captures a surge in corporate distress signals among US-listed companies, with three of four filings involving Nasdaq/NYSE delisting threats or actions on a single day (August 26, 2026). The cluster spans micro-cap and small-cap firms in industrials (Northann Corp.), telecom equipment (Cambium Networks), and battery technology (Microvast Holdings), suggesting a broad-based liquidity and compliance crisis rather than a sector-specific issue. Period-over-period data from the enriched filings reveals a pattern of deteriorating financial health: all three distressed companies show negative revenue growth trends (avg -12% YoY) and margin compression (avg -180 bps YoY), with no insider buying to signal management confidence. The fourth filing (Profusa, Inc.) narrowly avoided delisting after a reverse split, but its mixed sentiment and low materiality (6/10) indicate ongoing fragility. Critically, no forward-looking guidance or capital allocation actions (dividends, buybacks) were reported across any filing, underscoring a complete lack of positive catalysts. The most actionable insight is the timing cluster—three delisting events within one week—which may signal a broader regulatory crackdown or market liquidity event that investors should monitor for contagion risk.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 28, 2026

The USA Corporate Distress & Bankruptcy stream for August 28, 2026, reveals a severe wave of Nasdaq and NYSE American non-compliance events, with 14 filings concentrated on going concern warnings, delisting notices, and bankruptcy proceedings. The most critical development is the Chapter 11 filing of BioXcel Therapeutics, which has entered a stalking horse asset sale to Teva Pharmaceuticals for $57.5 million upfront, signaling a distressed exit for a biotech firm. A dominant theme is the cascade of Nasdaq minimum bid price and stockholders' equity failures, with 10 out of 14 companies receiving deficiency or delisting notices, many of which have already exhausted reverse stock split options (e.g., KALA BIO, GeoVax Labs). Period-over-period comparisons are limited due to the nature of the filings (8-Ks), but the data shows a clear pattern of deteriorating equity positions—My Size, Inc. reported equity of $2.347 million (below the $2.5 million threshold), and Oragenics Inc. reported $3.7 million (below $4 million). Insider trading activity is absent across all filings, which is a notable bearish signal as it suggests a lack of management confidence or an inability to trade due to blackout periods. Forward-looking statements are dominated by compliance plan deadlines and appeal processes, with no positive guidance revisions. The market implications are stark: a potential delisting wave could reduce liquidity and access to capital for these firms, while the BioXcel and Sangamo Therapeutics bankruptcies highlight the ongoing distress in the biotech sector. Portfolio-level patterns indicate that biotech and small-cap tech firms are the most vulnerable, with 6 out of 14 filings from biotech companies.

14 high priority 14 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026

The USA Bankruptcy & Insolvency stream for August 28, 2026, reveals a concentrated wave of biopharma Chapter 11 filings, with both BioXcel Therapeutics and Sangamo Therapeutics entering court-supervised restructuring to monetize core assets via stalking horse auctions. BioXcel's deal with Teva Pharmaceuticals for $57.5M upfront plus up to $87.5M in milestones provides a floor valuation, while Sangamo's sale of its Fabry gene therapy asset (ST-920) to PTC Therapeutics lacks disclosed upfront consideration, signaling potentially distressed pricing. Both filings underscore a sector theme of cash-constrained biotechs liquidating pipeline assets to repay creditors, with no revenue growth or insider buying to offset negative sentiment. The absence of period-over-period comparisons or forward guidance in these initial filings limits trend analysis, but the materiality scores (10/10 and 9/10) highlight high-impact events for investors monitoring bankruptcy recoveries and distressed asset valuations.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 27, 2026

The four filings in this digest paint a stark picture of distress across micro-cap and pre-revenue life sciences companies, with three of the four facing imminent Nasdaq delisting threats. The dominant theme is a cascade of compliance failures, including late filings (Lottery.com), sub-$1.00 bid prices (Rein Therapeutics, Onfolio Holdings), and insufficient stockholders' equity (SOBR Safe). Period-over-period data from the enriched filings reveals a sector-wide pattern of deteriorating financial health, with no company reporting revenue growth or margin expansion. Insider activity is notably absent in all filings, suggesting a lack of management conviction to deploy personal capital. The most critical development is SOBR Safe's multi-faceted delisting risk, compounded by a director resignation and a cumulative reverse stock split ratio of 1-for-1100, making it the highest-risk name. Onfolio Holdings is the sole positive outlier, having regained compliance through a reverse split, but this is a temporary fix rather than a fundamental turnaround. The portfolio-level pattern is a 'distress cascade' where companies cycle through bid price, equity, and filing deficiencies, often exhausting all remedies.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 25, 2026

Today's filings paint a stark picture of distress across micro-cap and pre-commercial biotech companies, with 6 out of 7 issuers receiving Nasdaq deficiency notices for bid price, market value, or late filing violations. The cluster of three late filers (BioRestorative, Maison Solutions, and La Rosa Holdings) signals systemic accounting and liquidity problems. La Rosa Holdings stands out as the most acute case, with liabilities exceeding assets by $7.8M and cash burning at a 26% QoQ rate. All companies have been granted extended compliance periods (late Q4 2026 through early Q2 2027), creating a series of critical 'cure-or-delist' deadlines. No insider trading activity or capital allocation events were reported in any filing, suggesting management teams are largely sidelined. The primary themes are Nasdaq delisting risks, going-concern doubts, and liquidity crises.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 24, 2026

This intelligence stream covers four US-listed companies facing severe corporate distress, including three new delisting/receivership events and one ongoing filing delinquency. The filings reveal a cluster of micro-cap companies (Senmiao Technology, Northann Corp., Bubblr Inc.) facing terminal liquidity crises, with negative equity, trading suspensions, and court-ordered receivership. Hub Group, a larger logistics firm, represents a different distress pattern: repeated filing delinquencies without immediate trading impact, suggesting internal control failures rather than insolvency. The most critical development is Bubblr Inc.'s court-appointed receivership (Materiality 10/10), which effectively transfers corporate control to a court officer. Across all filings, period-over-period data is sparse, but the absence of positive financial trends is notable—Senmiao's negative equity of -$35.3 million and Northann's multi-section NYSE American violations indicate systemic governance failures. No insider trading activity, capital allocation actions, or forward guidance were disclosed in any filing, which is itself a bearish signal for transparency. The overarching theme is a wave of micro-cap delistings concentrated in the same week (August 18-21, 2026), likely triggered by accelerated regulatory enforcement and deteriorating balance sheets. Investors should expect heightened volatility in these names as OTC trading begins and legal proceedings unfold.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 24, 2026

The sole filing for the USA Bankruptcy & Insolvency stream on this quiet session is a highly material 8-K from Bubblr Inc. (BBLR), revealing that a U.S. District Court has appointed a Receiver for the company. This receivership represents a severe adverse regulatory action, effectively removing management's control and signaling acute financial distress. The filing provides no financial metrics, period-over-period comparisons, or forward-looking guidance, which is typical for such a sudden and extreme corporate event. The appointment of a Receiver is a precursor to potential liquidation or a forced restructuring, making this the single most critical development in the stream. The lack of any other filings underscores a very quiet session, with this event dominating the bankruptcy and insolvency landscape for the day.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 21, 2026

A massive wave of 16 8-K filings on a single day (August 21, 2026) reveals an acute corporate distress event across the US public markets, primarily concentrated in the healthcare and technology sectors. A staggering 15 of the 16 filings are from companies receiving Nasdaq deficiency or delisting notices, with materiality ratings of 8/10 or 9/10 in nearly every case. The three primary distress triggers are: (1) failure to maintain the minimum $1.00 bid price (5 companies: VivoSim Labs, Citius, BioCardia, Pasithea, Estrella), (2) failure to meet the minimum $2.5 million stockholders' equity requirement (4 companies: Silexion, TruGolf, Dragonfly Energy, Adial), and (3) failure to timely file periodic reports (3 companies: Global Interactive, SolarMax, Synergy CHC). The most severe cases involve Silexion Therapeutics and Rain Enhancement Technologies, which have already received delisting notices with imminent hearing deadlines; their shareholders' equity of only $44,000 and failure to cure market value deficiencies, respectively, place them in the highest risk category. This concentration highlights systemic weakness in micro-cap and pre-revenue biotech/life sciences companies that have been unable to access follow-on capital in a challenging market environment. There is no benign explanation for this cluster; it is a fundamental capital structure crisis.

16 high priority 16 total filings